Q-omics provides the consensus-scored IFI6 profile across patient tissues and cancer cell-line models. IFI6 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, IFI6 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, IFI6 RNA expression shows 12,353 significant gene co-expression associations, with the highest sampling consensus in BLCA. Together, these results highlight LGG, HNSC, and BLCA as cancer lineages where IFI6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IFI6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IFI6 survival associations across molecular data types. IFI6 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IFI6 RNA expression–survival associations across cancer types. High IFI6 expression shows unfavorable associations in LGG, KIRC, UVM, ACC, THYM and HNSC. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for IFI6 RNA expression.
This table summarizes IFI6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for IFI6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IFI6 shows higher tumor expression in HNSC, BLCA, KIRC, STAD, COAD and BRCA. The HNSC box plot shows higher IFI6 RNA expression in tumor versus normal tissue (log2 FC = +5.401, t-test p < 0.001).
This table shows molecular features associated with IFI6 in patient tissues and cancer cell lines. In patient samples, IFI6 shows the broadest associations at the RNA and protein expression levels, with BLCA recurring as the lineage with the largest associated feature set. In cancer cell lines, IFI6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Lymphoma.
